Improving staging of rectal cancer in the pelvis: the role of PET/MRI
Onofrio A. Catalano(Harvard University), Bruce R. Rosen(Massachusetts General Hospital), Christy E. Cauley(Harvard University), Chiara Parente(SDN Istituto di Ricerca Diagnostica e Nucleare), Robin Striar(Harvard University), Rocco Ricciardi(Massachusetts General Hospital), Lina García Cañamaque(Hospital Universitario HM Sanchinarro), David Groshar(Tel Aviv University), Theodore S. Hong(Massachusetts General Hospital), Liliana Bordeianou(Massachusetts General Hospital), David L. Berger(Harvard University), Lale Umutlu(Essen University Hospital), Susanna I. Lee(Health Advances (United States)), Umar Mahmood(Athinoula A. Martinos Center for Biomedical Imaging), Felipe Furtado(Harvard University), David P. Ryan(East Carolina University), Marco Salvatore(Istituto Superiore di Sanità), Jennifer Y. Wo(Massachusetts General Hospital), Hiroko Kunitake(Massachusetts General Hospital), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Yan Li(Guiyang Medical University), Andrea Soricelli(Parthenope University of Naples)
Cited by 58
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
In vivo imaging of tumors with protease-activated near-infrared fluorescent probes
|Nature Biotechnology|1999|1.6k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k